Cargando…

Modern treatment outcomes for early T-stage oropharyngeal cancer treated with intensity-modulated radiation therapy at a tertiary care institution

BACKGROUND: Transoral surgery (TOS), particularly transoral robotic surgery (TORS) has become the preferred modality in the United States for the treatment of early stage oropharyngeal cancer, largely due to assumptions of fewer toxicities and improved quality of life compared to primary radiotherap...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Gravio, Eric J., Lang, Pencilla, Kim, Hugh Andrew Jinwook, Chinnery, Tricia, Mundi, Neil, MacNeil, S. Danielle, Mendez, Adrian, Yoo, John, Fung, Kevin, Mymryk, Joe S., Barrett, John W., Read, Nancy, Venkatesan, Varagur, Kuruvilla, Sara, Mendez, Lucas C., Winquist, Eric, Mitchell, Sylvia, Mattonen, Sarah A., Nichols, Anthony C., Palma, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654053/
https://www.ncbi.nlm.nih.gov/pubmed/33168055
http://dx.doi.org/10.1186/s13014-020-01705-1
_version_ 1783608001404338176
author Di Gravio, Eric J.
Lang, Pencilla
Kim, Hugh Andrew Jinwook
Chinnery, Tricia
Mundi, Neil
MacNeil, S. Danielle
Mendez, Adrian
Yoo, John
Fung, Kevin
Mymryk, Joe S.
Barrett, John W.
Read, Nancy
Venkatesan, Varagur
Kuruvilla, Sara
Mendez, Lucas C.
Winquist, Eric
Mitchell, Sylvia
Mattonen, Sarah A.
Nichols, Anthony C.
Palma, David A.
author_facet Di Gravio, Eric J.
Lang, Pencilla
Kim, Hugh Andrew Jinwook
Chinnery, Tricia
Mundi, Neil
MacNeil, S. Danielle
Mendez, Adrian
Yoo, John
Fung, Kevin
Mymryk, Joe S.
Barrett, John W.
Read, Nancy
Venkatesan, Varagur
Kuruvilla, Sara
Mendez, Lucas C.
Winquist, Eric
Mitchell, Sylvia
Mattonen, Sarah A.
Nichols, Anthony C.
Palma, David A.
author_sort Di Gravio, Eric J.
collection PubMed
description BACKGROUND: Transoral surgery (TOS), particularly transoral robotic surgery (TORS) has become the preferred modality in the United States for the treatment of early stage oropharyngeal cancer, largely due to assumptions of fewer toxicities and improved quality of life compared to primary radiotherapy (RT). However, these assumptions are based on retrospective analysis, a subset of which utilize primary RT groups not limited to T1-2 stage tumors for which transoral robotic surgery is FDA approved. Thus, there is potential for underestimating survival and overestimating toxicity, including treatment related mortality, in primary RT. METHODS: Consecutive cases of early T-stage (T1–T2) oropharyngeal cancer presenting to the London Health Sciences Centre between 2014 and 2018 treated with RT or chemoradiation (CRT) were reviewed. Patient demographics, treatment details, survival outcomes and toxicity were collected. Toxicities were retrospectively graded using the Common Terminology Criteria for Adverse Events criteria. RESULTS: A total of 198 patients were identified, of which 82% were male and 73% were HPV-positive. Sixty-eight percent of patients experienced a grade 2 toxicity, 48% a grade 3 and 4% a grade 4. The most frequent toxicities were dysphagia, neutropenia and ototoxicity. The rates of gastrostomy tube dependence at 1 and 2 years were 2.5% and 1% respectively. There were no grade 5 (fatal) toxicities. HPV-positive patients experienced improved 5-year overall survival (86% vs 64%, p = 0.0026). CONCLUSIONS: Primary RT or CRT provides outstanding survival for early T-stage disease, with low rates of severe toxicity and feeding tube dependence. This study provides a reference for comparison for patients treated with primary transoral surgery.
format Online
Article
Text
id pubmed-7654053
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-76540532020-11-10 Modern treatment outcomes for early T-stage oropharyngeal cancer treated with intensity-modulated radiation therapy at a tertiary care institution Di Gravio, Eric J. Lang, Pencilla Kim, Hugh Andrew Jinwook Chinnery, Tricia Mundi, Neil MacNeil, S. Danielle Mendez, Adrian Yoo, John Fung, Kevin Mymryk, Joe S. Barrett, John W. Read, Nancy Venkatesan, Varagur Kuruvilla, Sara Mendez, Lucas C. Winquist, Eric Mitchell, Sylvia Mattonen, Sarah A. Nichols, Anthony C. Palma, David A. Radiat Oncol Research BACKGROUND: Transoral surgery (TOS), particularly transoral robotic surgery (TORS) has become the preferred modality in the United States for the treatment of early stage oropharyngeal cancer, largely due to assumptions of fewer toxicities and improved quality of life compared to primary radiotherapy (RT). However, these assumptions are based on retrospective analysis, a subset of which utilize primary RT groups not limited to T1-2 stage tumors for which transoral robotic surgery is FDA approved. Thus, there is potential for underestimating survival and overestimating toxicity, including treatment related mortality, in primary RT. METHODS: Consecutive cases of early T-stage (T1–T2) oropharyngeal cancer presenting to the London Health Sciences Centre between 2014 and 2018 treated with RT or chemoradiation (CRT) were reviewed. Patient demographics, treatment details, survival outcomes and toxicity were collected. Toxicities were retrospectively graded using the Common Terminology Criteria for Adverse Events criteria. RESULTS: A total of 198 patients were identified, of which 82% were male and 73% were HPV-positive. Sixty-eight percent of patients experienced a grade 2 toxicity, 48% a grade 3 and 4% a grade 4. The most frequent toxicities were dysphagia, neutropenia and ototoxicity. The rates of gastrostomy tube dependence at 1 and 2 years were 2.5% and 1% respectively. There were no grade 5 (fatal) toxicities. HPV-positive patients experienced improved 5-year overall survival (86% vs 64%, p = 0.0026). CONCLUSIONS: Primary RT or CRT provides outstanding survival for early T-stage disease, with low rates of severe toxicity and feeding tube dependence. This study provides a reference for comparison for patients treated with primary transoral surgery. BioMed Central 2020-11-10 /pmc/articles/PMC7654053/ /pubmed/33168055 http://dx.doi.org/10.1186/s13014-020-01705-1 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Di Gravio, Eric J.
Lang, Pencilla
Kim, Hugh Andrew Jinwook
Chinnery, Tricia
Mundi, Neil
MacNeil, S. Danielle
Mendez, Adrian
Yoo, John
Fung, Kevin
Mymryk, Joe S.
Barrett, John W.
Read, Nancy
Venkatesan, Varagur
Kuruvilla, Sara
Mendez, Lucas C.
Winquist, Eric
Mitchell, Sylvia
Mattonen, Sarah A.
Nichols, Anthony C.
Palma, David A.
Modern treatment outcomes for early T-stage oropharyngeal cancer treated with intensity-modulated radiation therapy at a tertiary care institution
title Modern treatment outcomes for early T-stage oropharyngeal cancer treated with intensity-modulated radiation therapy at a tertiary care institution
title_full Modern treatment outcomes for early T-stage oropharyngeal cancer treated with intensity-modulated radiation therapy at a tertiary care institution
title_fullStr Modern treatment outcomes for early T-stage oropharyngeal cancer treated with intensity-modulated radiation therapy at a tertiary care institution
title_full_unstemmed Modern treatment outcomes for early T-stage oropharyngeal cancer treated with intensity-modulated radiation therapy at a tertiary care institution
title_short Modern treatment outcomes for early T-stage oropharyngeal cancer treated with intensity-modulated radiation therapy at a tertiary care institution
title_sort modern treatment outcomes for early t-stage oropharyngeal cancer treated with intensity-modulated radiation therapy at a tertiary care institution
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7654053/
https://www.ncbi.nlm.nih.gov/pubmed/33168055
http://dx.doi.org/10.1186/s13014-020-01705-1
work_keys_str_mv AT digravioericj moderntreatmentoutcomesforearlytstageoropharyngealcancertreatedwithintensitymodulatedradiationtherapyatatertiarycareinstitution
AT langpencilla moderntreatmentoutcomesforearlytstageoropharyngealcancertreatedwithintensitymodulatedradiationtherapyatatertiarycareinstitution
AT kimhughandrewjinwook moderntreatmentoutcomesforearlytstageoropharyngealcancertreatedwithintensitymodulatedradiationtherapyatatertiarycareinstitution
AT chinnerytricia moderntreatmentoutcomesforearlytstageoropharyngealcancertreatedwithintensitymodulatedradiationtherapyatatertiarycareinstitution
AT mundineil moderntreatmentoutcomesforearlytstageoropharyngealcancertreatedwithintensitymodulatedradiationtherapyatatertiarycareinstitution
AT macneilsdanielle moderntreatmentoutcomesforearlytstageoropharyngealcancertreatedwithintensitymodulatedradiationtherapyatatertiarycareinstitution
AT mendezadrian moderntreatmentoutcomesforearlytstageoropharyngealcancertreatedwithintensitymodulatedradiationtherapyatatertiarycareinstitution
AT yoojohn moderntreatmentoutcomesforearlytstageoropharyngealcancertreatedwithintensitymodulatedradiationtherapyatatertiarycareinstitution
AT fungkevin moderntreatmentoutcomesforearlytstageoropharyngealcancertreatedwithintensitymodulatedradiationtherapyatatertiarycareinstitution
AT mymrykjoes moderntreatmentoutcomesforearlytstageoropharyngealcancertreatedwithintensitymodulatedradiationtherapyatatertiarycareinstitution
AT barrettjohnw moderntreatmentoutcomesforearlytstageoropharyngealcancertreatedwithintensitymodulatedradiationtherapyatatertiarycareinstitution
AT readnancy moderntreatmentoutcomesforearlytstageoropharyngealcancertreatedwithintensitymodulatedradiationtherapyatatertiarycareinstitution
AT venkatesanvaragur moderntreatmentoutcomesforearlytstageoropharyngealcancertreatedwithintensitymodulatedradiationtherapyatatertiarycareinstitution
AT kuruvillasara moderntreatmentoutcomesforearlytstageoropharyngealcancertreatedwithintensitymodulatedradiationtherapyatatertiarycareinstitution
AT mendezlucasc moderntreatmentoutcomesforearlytstageoropharyngealcancertreatedwithintensitymodulatedradiationtherapyatatertiarycareinstitution
AT winquisteric moderntreatmentoutcomesforearlytstageoropharyngealcancertreatedwithintensitymodulatedradiationtherapyatatertiarycareinstitution
AT mitchellsylvia moderntreatmentoutcomesforearlytstageoropharyngealcancertreatedwithintensitymodulatedradiationtherapyatatertiarycareinstitution
AT mattonensaraha moderntreatmentoutcomesforearlytstageoropharyngealcancertreatedwithintensitymodulatedradiationtherapyatatertiarycareinstitution
AT nicholsanthonyc moderntreatmentoutcomesforearlytstageoropharyngealcancertreatedwithintensitymodulatedradiationtherapyatatertiarycareinstitution
AT palmadavida moderntreatmentoutcomesforearlytstageoropharyngealcancertreatedwithintensitymodulatedradiationtherapyatatertiarycareinstitution